CaSR Inhibitors
1 drugsAbout CaSR
The Calcium-Sensing Receptor (CaSR) is a GPCR crucial for maintaining calcium homeostasis. Activated by changes in extracellular calcium, it triggers intracellular signaling cascades regulating physiological processes.
Currently, there is no genetic evidence directly linking CaSR to specific diseases. However, the existence of PARSABIV, an FDA-approved drug, underscores its importance as a therapeutic target.
CaSR is targeted by one FDA-approved peptide drug, PARSABIV, developed by KAI PHARMS INC. This drug addresses a therapeutic area categorized as 'other,' suggesting niche applications.
Top CaSR Drugs
KAI PHARMS INC is the only company with an approved CaSR-targeting drug.
The market is highly concentrated, presenting a high barrier to entry unless differentiated mechanisms are pursued.
CaSR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CaSR, using peptide modality.
Explore small molecule or antibody modalities to diversify the therapeutic approach and expand market potential.
CaSR Clinical Trials 20 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CaSR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 | 100% |
| Phase 2 | 6 | 5 | 1 | 0 | 83% |
| Phase 3 | 9 | 7 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved CaSR drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting CaSR. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
CaSR Drug Approval Timeline (2017 - 2017)
PARSABIV was first approved in 2017 and remains the most recent approval.
The approval timeline suggests a lack of recent innovation; new CaSR-targeting therapies could revitalize the field.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 5 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CaSR. A trial counts if an approved drug acting on CaSR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.